Status:
COMPLETED
A Study for Teriparatide in Severe Osteoporosis
Lead Sponsor:
Eli Lilly and Company
Conditions:
Osteoporosis, Postmenopausal
Osteoporosis
Eligibility:
All Genders
21+ years
Brief Summary
This observational study will evaluate the incidence of new vertebral and non vertebral fragility fractures in patients with severe osteoporosis treated with anabolic drugs. This study will also evalu...
Detailed Description
The participants should be treated with anabolic therapy for osteoporosis (Teriparatide or PTH 1-84) for 18 months and should be followed up for subsequent 6 months. The treatment is expected to impro...
Eligibility Criteria
Inclusion
- Postmenopausal women and men older than 21 years affected by severe osteoporosis with an incidental vertebral or hip fracture during treatment with an antiresorptive, or having 3 or more severe vertebral fractures or having 2 severe vertebral fractures and an historical hip fracture.
Exclusion
- Any contraindication for the use of antiosteoporotic drug
- Premenopausal women or men younger than 21 years
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
794 Patients enrolled
Trial Details
Trial ID
NCT00696644
Start Date
June 1 2008
End Date
April 1 2011
Last Update
May 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this study, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Valeggio sul Mincio, Verona, Italy, 36067